1.21
-0.03(-2.42%)
Currency In USD
| Previous Close | 1.24 |
| Open | 1.23 |
| Day High | 1.28 |
| Day Low | 1.21 |
| 52-Week High | 10.02 |
| 52-Week Low | 1.08 |
| Volume | 55,453 |
| Average Volume | 44,744 |
| Market Cap | 3.83M |
| PE | -0.1 |
| EPS | -12.07 |
| Moving Average 50 Days | 1.24 |
| Moving Average 200 Days | 2.42 |
| Change | -0.03 |
If you invested $1000 in Sonnet BioTherapeutics Holdings, Inc. (SONN) 10 years ago, it would be worth $0 as of July 02, 2025 at a share price of $1.21. Whereas If you bought $1000 worth of Sonnet BioTherapeutics Holdings, Inc. (SONN) shares 5 years ago, it would be worth $0.07 as of July 02, 2025 at a share price of $1.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit
GlobeNewswire Inc.
May 01, 2025 1:00 PM GMT
PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment (TME), today announc
Sonnet Releases Virtual Investor "What This Means" Segment
GlobeNewswire Inc.
Apr 16, 2025 1:10 PM GMT
- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010 - Watch the "What This Means" video here PRINCETON, N.J., April 16, 2025 (GLOBE NE
Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose
GlobeNewswire Inc.
Apr 04, 2025 1:00 PM GMT
Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq®) The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg in combination with atezolizumab in patients with platinum-resist